BR9602209A - Compostos composição farmacêutica e método para tratar uma condição para aumentar o teor de carne para tratar doenças da próstata perturbações da motilidade intestinal depressão dislipidemia e afecções inflamatórias das vias respiratórias - Google Patents
Compostos composição farmacêutica e método para tratar uma condição para aumentar o teor de carne para tratar doenças da próstata perturbações da motilidade intestinal depressão dislipidemia e afecções inflamatórias das vias respiratóriasInfo
- Publication number
- BR9602209A BR9602209A BR9602209A BR9602209A BR9602209A BR 9602209 A BR9602209 A BR 9602209A BR 9602209 A BR9602209 A BR 9602209A BR 9602209 A BR9602209 A BR 9602209A BR 9602209 A BR9602209 A BR 9602209A
- Authority
- BR
- Brazil
- Prior art keywords
- treat
- dyslipidemia
- condition
- pharmaceutical composition
- increase
- Prior art date
Links
- 208000032928 Dyslipidaemia Diseases 0.000 title 1
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000008991 intestinal motility Effects 0.000 title 1
- 235000013372 meat Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000017497 prostate disease Diseases 0.000 title 1
- 210000002345 respiratory system Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB1995/000344 WO1996035671A1 (en) | 1995-05-10 | 1995-05-10 | β-ADRENERGIC AGONISTS |
| CA002220399A CA2220399A1 (en) | 1995-05-10 | 1995-05-10 | .beta.-adrenergic agonists |
| HU9601240A HUP9601240A1 (en) | 1995-05-10 | 1996-05-09 | Pyridin and pyrimidin derivatives, suitable as beta-adrenerg agonists, pharmaceutical compositions containing the same and their intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9602209A true BR9602209A (pt) | 1998-04-07 |
Family
ID=89993954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9602209A BR9602209A (pt) | 1995-05-10 | 1996-05-10 | Compostos composição farmacêutica e método para tratar uma condição para aumentar o teor de carne para tratar doenças da próstata perturbações da motilidade intestinal depressão dislipidemia e afecções inflamatórias das vias respiratórias |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5977124A (pt) |
| EP (1) | EP0824519A1 (pt) |
| JP (1) | JPH11504649A (pt) |
| KR (1) | KR100190259B1 (pt) |
| AU (1) | AU706235B2 (pt) |
| BR (1) | BR9602209A (pt) |
| CA (1) | CA2220399A1 (pt) |
| CO (1) | CO4440567A1 (pt) |
| CZ (1) | CZ132196A3 (pt) |
| FI (1) | FI974172A0 (pt) |
| HU (1) | HUP9601240A1 (pt) |
| IL (1) | IL118115A0 (pt) |
| MX (1) | MX9708621A (pt) |
| NO (1) | NO307049B1 (pt) |
| NZ (1) | NZ286548A (pt) |
| PL (1) | PL314120A1 (pt) |
| SG (1) | SG43365A1 (pt) |
| TR (1) | TR199600358A2 (pt) |
| WO (1) | WO1996035671A1 (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011113120A1 (pt) | 2009-09-01 | 2011-09-22 | Antonio Carlos Nunes Da Silva | Usina processadora de resíduos urbanos |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981562A (en) * | 1996-01-30 | 1999-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6031105A (en) * | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
| US6008361A (en) * | 1996-04-09 | 1999-12-28 | Pfizer Inc. | Substituted pyridines |
| KR20000053314A (ko) | 1996-11-14 | 2000-08-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 치환된 피리딘의 제조 방법 |
| US6001856A (en) * | 1997-06-13 | 1999-12-14 | Pfizer Inc. | β-adrenergic agonists to reduce a wasting condition |
| EP0920864A1 (en) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| US6657063B1 (en) * | 1998-04-30 | 2003-12-02 | Pfizer Inc. | Combinations of β3 agonists and growth hormone secretagogues |
| US6090942A (en) * | 1998-10-15 | 2000-07-18 | Pfizer Inc. | Process and intermediates for a β3 -adrenergic receptor agonist |
| ES2228413T3 (es) | 1999-07-23 | 2005-04-16 | Pfizer Products Inc. | Productos intermedios y un procedimiento para producir agonistas de receptores beta-adrenergicos. |
| CA2386474A1 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| US6451587B1 (en) | 1999-09-29 | 2002-09-17 | Pfizer Inc. | Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone |
| CA2407538C (en) * | 2000-04-28 | 2007-01-09 | Asahi Kasei Kabushiki Kaisha | Novel bicyclic compounds |
| KR20030044013A (ko) * | 2000-10-20 | 2003-06-02 | 화이자 프로덕츠 인코포레이티드 | 알파-아릴 에탄올아민 및 이들의 베타-3 아드레날린성수용체 작용제로서의 용도 |
| EP1236723A1 (en) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
| AU2003209527A1 (en) * | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| BR0307996A (pt) | 2002-02-27 | 2004-12-07 | Pfizer Prod Inc | Processos e intermediários úteis na preparação de receptores de agonistas beta3-adrenérgicos |
| DOP2003000587A (es) * | 2002-02-27 | 2003-08-30 | Pfizer Prod Inc | AGONISTAS DEL RECEPTOR ß3-ADRENERGICO |
| US20050075323A1 (en) * | 2003-03-05 | 2005-04-07 | Pfizer Inc | Beta3 adrenergic receptor agonists and uses thereof |
| EP1477167A1 (en) * | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| GB0312832D0 (en) * | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| US7375100B2 (en) * | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
| CA2551167C (en) * | 2003-12-23 | 2011-10-18 | Astellas Pharma Inc. | Aminoalcohol derivatives |
| WO2006051373A1 (en) * | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| WO2006133160A2 (en) | 2005-06-06 | 2006-12-14 | Georgetown University | Compositions and methods for lipo modeling |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358455A (en) * | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
| EP0105053B1 (en) * | 1982-10-01 | 1988-01-20 | Merck & Co. Inc. | Aralkylaminoethanol heterocyclic compounds |
| CA1287061C (en) * | 1986-06-27 | 1991-07-30 | Roche Holding Ltd. | Pyridine ethanolamine derivatives |
| GB8703007D0 (en) * | 1987-02-10 | 1987-03-18 | Glaxo Group Ltd | Chemical compounds |
| NZ226991A (en) * | 1987-11-27 | 1992-03-26 | Merck & Co Inc | Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors |
| US5019578A (en) * | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| US5216170A (en) * | 1989-01-26 | 1993-06-01 | Bayer Aktiengesellschaft | (2-aminopropyl) pyridines useful as intermediates |
| GB9209076D0 (en) * | 1992-04-27 | 1992-06-10 | Ici Plc | Chemical compounds |
| JPH08502278A (ja) * | 1992-10-16 | 1996-03-12 | ビイク ネダーラント ベスローテン フェンノートシャップ | 置換されたエタノールアミンエステル |
| US5726192A (en) * | 1992-12-29 | 1998-03-10 | Smithkline Beecham Corporation | Platelet aggregation inhibiting compounds |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| JPH08509491A (ja) * | 1993-04-26 | 1996-10-08 | 藤沢薬品工業株式会社 | 胃腸疾患の治療に有用なエタノールアミン誘導体 |
| ATE154935T1 (de) * | 1993-06-14 | 1997-07-15 | Pfizer | Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit |
| JPH08165276A (ja) * | 1994-12-14 | 1996-06-25 | Dainippon Pharmaceut Co Ltd | ２−アルキルアミノ−１−フェニルエタノール誘導体 |
-
1995
- 1995-05-10 JP JP8533903A patent/JPH11504649A/ja active Pending
- 1995-05-10 MX MX9708621A patent/MX9708621A/es not_active Application Discontinuation
- 1995-05-10 US US08/945,551 patent/US5977124A/en not_active Expired - Fee Related
- 1995-05-10 WO PCT/IB1995/000344 patent/WO1996035671A1/en not_active Application Discontinuation
- 1995-05-10 EP EP95915995A patent/EP0824519A1/en not_active Ceased
- 1995-05-10 CA CA002220399A patent/CA2220399A1/en not_active Abandoned
-
1996
- 1996-05-02 IL IL11811596A patent/IL118115A0/xx unknown
- 1996-05-03 TR TR96/00358A patent/TR199600358A2/xx unknown
- 1996-05-07 CZ CZ961321A patent/CZ132196A3/cs unknown
- 1996-05-07 SG SG1996009751A patent/SG43365A1/en unknown
- 1996-05-08 PL PL96314120A patent/PL314120A1/xx unknown
- 1996-05-08 CO CO96022964A patent/CO4440567A1/es unknown
- 1996-05-09 NZ NZ286548A patent/NZ286548A/en unknown
- 1996-05-09 HU HU9601240A patent/HUP9601240A1/hu unknown
- 1996-05-09 KR KR1019960015262A patent/KR100190259B1/ko not_active IP Right Cessation
- 1996-05-09 NO NO961887A patent/NO307049B1/no not_active IP Right Cessation
- 1996-05-09 AU AU52185/96A patent/AU706235B2/en not_active Ceased
- 1996-05-10 BR BR9602209A patent/BR9602209A/pt active Search and Examination
-
1997
- 1997-11-07 FI FI974172A patent/FI974172A0/fi unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011113120A1 (pt) | 2009-09-01 | 2011-09-22 | Antonio Carlos Nunes Da Silva | Usina processadora de resíduos urbanos |
Also Published As
| Publication number | Publication date |
|---|---|
| PL314120A1 (en) | 1996-11-12 |
| NZ286548A (en) | 1998-03-25 |
| SG43365A1 (en) | 1997-10-17 |
| NO961887L (no) | 1996-11-11 |
| CZ132196A3 (en) | 1997-03-12 |
| CA2220399A1 (en) | 1996-11-14 |
| HU9601240D0 (en) | 1996-07-29 |
| AU706235B2 (en) | 1999-06-10 |
| KR100190259B1 (ko) | 1999-06-01 |
| JPH11504649A (ja) | 1999-04-27 |
| AU5218596A (en) | 1996-11-21 |
| WO1996035671A1 (en) | 1996-11-14 |
| EP0824519A1 (en) | 1998-02-25 |
| MX9708621A (es) | 1998-02-28 |
| IL118115A0 (en) | 1996-09-12 |
| FI974172A (fi) | 1997-11-07 |
| TR199600358A2 (tr) | 1996-11-21 |
| US5977124A (en) | 1999-11-02 |
| HUP9601240A1 (en) | 1997-09-29 |
| NO961887D0 (no) | 1996-05-09 |
| KR960041168A (ko) | 1996-12-19 |
| CO4440567A1 (es) | 1997-05-07 |
| FI974172A0 (fi) | 1997-11-07 |
| NO307049B1 (no) | 2000-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9602209A (pt) | Compostos composição farmacêutica e método para tratar uma condição para aumentar o teor de carne para tratar doenças da próstata perturbações da motilidade intestinal depressão dislipidemia e afecções inflamatórias das vias respiratórias | |
| BR9710372A (pt) | Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase | |
| NO20010749L (no) | Forebygging av luftveis mukusproduksjon ved administrering av EGF-R-antagonister | |
| FR13C0060I2 (fr) | Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques | |
| PT944631E (pt) | Novos derivados substituidos de pirazole para tratamento de doencas cardiovasculares | |
| DE69931042D1 (de) | Stoffe mit serotoninartiger wirkung zur behandlung der schlafapnoe | |
| NO963568D0 (no) | Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse | |
| NO992641D0 (no) | Blandinger og fremgangsmÕter for behandling eller forhindring av betennelsessykdommer | |
| NO972972L (no) | Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse | |
| BR9611563A (pt) | Composto composição farmacêutica método de tratamento de uma doença inflamatória e ensaio para detectar inibidores de agrecanase | |
| BR9702745A (pt) | Processo para produzir o teor de gordura da carne e produto de carne com teor de gordura muito baixo | |
| DE69429202D1 (de) | Therapeutischer Wirkstoff für Erkrankungen des Verdauungstraktes | |
| DE69028712D1 (de) | Zusammensetzung zur behandlung entzündlicher darmerkrankungen | |
| DK0951909T3 (da) | Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf | |
| BR9607967A (pt) | Uso de composições imunomodulares extraídas da bile para o tratamento das desordens do sistema imunológico fabricação do medicamento e emprego do mesmo | |
| BR9611555A (pt) | Compostos formulação farmacêutica utilização de um composto processo para tratamento de uma doença obstrutiva reversível das vias aéreas e para preparação do composto | |
| BR0312696A (pt) | Tratamento tópico de doenças da pele | |
| BR0214075A (pt) | Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação | |
| LV10689A (lv) | Dimetilpolisiloksana pielietojums kunga un zarnu trakta slimibu arstesanai | |
| PT900563E (pt) | Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas | |
| PT1150681E (pt) | Utilizacao de uma composicao farmaceutica que contem desoxipeganina para o tratamento da dependencia da nicotina | |
| NO995231D0 (no) | Terapeutisk behandling av hudlidelser | |
| BR9806083A (pt) | Composi-Æo farmac-utica para o tratamento da hapattite c | |
| DZ3225A1 (fr) | Methode et compositions pour le traitement des maladies pulmonaires | |
| BR9812531A (pt) | Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB34 | Technical and formal requirements: requirement - article 34 of industrial property law | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |